SUBSCRIBE
SUBSCRIBE
Greg Slabodkin

Greg Slabodkin

Greg is a seasoned editor/writer who has covered the healthcare, life sciences and medical device industries for several tech trade publications. He is the recipient of a Post-Newsweek Business Information Editorial Excellence Award for his news reporting and a Gold Award for Best Case Study from the American Society of Healthcare Publication Editors. In addition, Greg is a Healthcare Fellow from the Society for Advancing Business Editing and Writing. He is an avid Buffalo Bills football fan, likes to kayak and plays guitar.

Drug Development
Listen: JPM2024 Day 2 Highlights
The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 2 at JPM2024.
January 9, 2024
 · 
1 min read
 · 
Lori Ellis
Pictured: Gene therapy illustration showing an inj
Policy
Gene Therapy Approvals Expected to Ramp Up in 2024 Amid Manufacturing, Cost Challenges
The Alliance for Regenerative Medicine predicts up to 17 cell and gene therapy approvals this year and defends high prices, while FDA’s Peter Marks expresses concern about manufacturing costs.
January 9, 2024
 · 
4 min read
 · 
Greg Slabodkin
Front view of the White House
Policy
Biopharma Policy in the Spotlight at JPM as Sector Gears Up for Volatile 2024
The Inflation Reduction Act, “march-in rights” to take back patents and M&A were among the issues discussed at a Sunday panel in San Francisco ahead of Monday’s start of the J.P. Morgan conference.
January 8, 2024
 · 
4 min read
 · 
Greg Slabodkin
Pictured: Bay Bridge and San Francisco sky
JPM Offers First Glimpse of What 2024 Might Portend for Biopharma Sector
After a topsy-turvy 2023, thousands of industry stakeholders will attend next week’s J.P. Morgan Healthcare Conference in San Francisco to answer a fundamental question: What will this year look like?
January 5, 2024
 · 
2 min read
 · 
Greg Slabodkin
Pictured: Illustration of professionals interactin
2023 Year in Review: Biopharma Takes One Step Forward, Two Steps Back
It has been a topsy-turvy year marked by record bankruptcies, a sharp drop in funding, few IPOs, and a steady stream of layoffs and regulatory challenges offset by M&A deals and the hot weight loss and antibody-drug conjugate markets.
December 22, 2023
 · 
3 min read
 · 
Greg Slabodkin
Drug Development
Every move you make: Biopharma industry under heavy scrutiny
On this episode of the Weekly: Biden administration puts pressure on the biopharma industry; renewed interest in psychedelics after MindMed announces LSD-based candidate meets primary endpoint; bluebird changes its tune.
December 20, 2023
 · 
1 min read
 · 
Lori Ellis
Policy
Biden, Big Pharma Increasingly at Loggerheads in Run-Up to 2024 Election
President Joe Biden has long promised to stand up to Big Pharma, lower prescription drug prices and limit the power of drugmakers—a pledge he seems intent on keeping.
December 15, 2023
 · 
3 min read
 · 
Greg Slabodkin
FDA
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny
This week, we discuss the two major FDA approvals for sickle cell from Vertex/CRISPR and bluebird bio; Axcella and the future of long-covid treatments, Vanda’s $100m purchase and AI regulatory developments in Europe.
December 13, 2023
 · 
1 min read
 · 
Lori Ellis
FDA
Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun
Friday’s FDA approval of Vertex-CRISPR’s Casgevy and bluebird bio’s Lyfgenia has immediately revealed startling differences between these two gene therapies: price and a black-box warning.
December 8, 2023
 · 
2 min read
 · 
Greg Slabodkin
Drug Development
ADC and GLP-1 Rocket Ride Continues as 2023 Comes to Close
AbbVie’s $10.1 billion ImmunoGen buy and Altimmune’s Phase II win demonstrate that the antibody-drug conjugate market is red hot in cancer and GLP-1 drugs for weight loss are an absolute craze.
December 1, 2023
 · 
3 min read
 · 
Greg Slabodkin
Deals
Deals, Dupixent and GLP-1 drug shortages
This week on The Weekly we talk struggles with ⁠GLP-1 drug shortages⁠ and what that might mean for Novo and Lilly competitors; Regeneron and Sanofi positive results for ⁠⁠⁠Dupixent⁠⁠⁠ in COPD. Plus, Merck ⁠buys Caraway⁠, Beigene’s ⁠deal⁠ with Ensem, ⁠ups⁠ and ⁠downs⁠ for Flagship.
November 29, 2023
 · 
1 min read
 · 
Lori Ellis
Drug Development
First ever CRISPR gene therapy approval: What happens next?
CRISPR gene-editing has had its first ever approval in the UK. Will the FDA follow suit? What can patients expect the price tag to be?
November 21, 2023
 · 
1 min read
 · 
Greg Slabodkin
CRISPR-Cas9 genome editing enzyme, 3d illustration
Policy
Welcome to the Brave New World of CRISPR Gene Editing
The U.K.’s conditional marketing authorization for Vertex Pharmaceuticals and CRISPR Therapeutics’ gene-edited therapy exa-cel raises some potential safety concerns with the risk of off-target effects.
November 17, 2023
 · 
3 min read
 · 
Greg Slabodkin
FDA
Lilly’s Zepbound vs. Novo’s Wegovy: The Weight-Loss Drug Race Has Officially Started
The FDA’s approval of Eli Lilly’s obesity drug Zepbound intensifies an already heated battle with Novo Nordisk’s Wegovy in the lucrative weight-loss drug market, as other drugmakers hope to get a piece of the action.
November 10, 2023
 · 
2 min read
 · 
Greg Slabodkin
Buildings encompassing arrows pointing upward © Ni
Business
Novo, Lilly Weight-Loss Drug Juggernaut Has Nowhere to Go But Up
Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro drove blockbuster sales in the third quarter and the sky’s the limit for the duopoly. The only limiting factor is that the frenzied demand for their respective drugs is outpacing supply.
November 3, 2023
 · 
2 min read
 · 
Greg Slabodkin
Load More